• Something wrong with this record ?

Peroneal Electrical Transcutaneous NeuroModulation as a New Treatment for Patients with Overactive Bladder: An Initial Clinical Experience

J. Krhut, M. Rejchrt, B. Skugarevska, M. Grepl, P. Zvara

. 2022 ; 106 (7) : 658-663. [pub] 20220322

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22025500

INTRODUCTION: The aim of this study was to determine whether peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) using the URIS® neuromodulation system can be used in individuals with refractory overactive bladder (OAB). METHODS: Eighteen female patients with idiopathic OAB who failed previous behavioral and pharmacological therapy were enrolled. Patients were treated with the URIS® neuromodulation system using active electrodes placed on the popliteal fossa, targeting the peroneal nerve for 30 min once a week for 12 weeks. Changes in OAB symptoms and patient-reported outcomes from baseline to the end of the study were analyzed. A nonparametric Wilcoxon signed-rank test was used to assess changes in variables. Statistical significance was defined as p ≤ 0.05. RESULTS: We observed a significant reduction in micturition frequency (p = 0.022), number of severe urgency episodes (p < 0.001), urgency incontinence episodes (p = 0.001), and nocturia episodes (p = 0.027). A decrease in Patient Perception of Bladder Condition score (p < 0.001) was also observed. Posttreatment, 15 patients (83.3%) reported a moderate or significant reduction in their bladder bother. Throughout the study, two adverse events were recorded with no causal relationship to the study treatment. DISCUSSION/CONCLUSIONS: Our study documented a significant reduction in all OAB symptoms and an improvement in all patient-reported outcomes in patients treated with peroneal eTNM® using the URIS® neuromodulation system.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025500
003      
CZ-PrNML
005      
20221031100513.0
007      
ta
008      
221017s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000522570 $2 doi
035    __
$a (PubMed)35316811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Krhut, Jan $u Department of Urology, University Hospital, Ostrava, Czechia $u Department of Surgical Studies, Medical Faculty, Ostrava University, Ostrava, Czechia
245    10
$a Peroneal Electrical Transcutaneous NeuroModulation as a New Treatment for Patients with Overactive Bladder: An Initial Clinical Experience / $c J. Krhut, M. Rejchrt, B. Skugarevska, M. Grepl, P. Zvara
520    9_
$a INTRODUCTION: The aim of this study was to determine whether peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) using the URIS® neuromodulation system can be used in individuals with refractory overactive bladder (OAB). METHODS: Eighteen female patients with idiopathic OAB who failed previous behavioral and pharmacological therapy were enrolled. Patients were treated with the URIS® neuromodulation system using active electrodes placed on the popliteal fossa, targeting the peroneal nerve for 30 min once a week for 12 weeks. Changes in OAB symptoms and patient-reported outcomes from baseline to the end of the study were analyzed. A nonparametric Wilcoxon signed-rank test was used to assess changes in variables. Statistical significance was defined as p ≤ 0.05. RESULTS: We observed a significant reduction in micturition frequency (p = 0.022), number of severe urgency episodes (p < 0.001), urgency incontinence episodes (p = 0.001), and nocturia episodes (p = 0.027). A decrease in Patient Perception of Bladder Condition score (p < 0.001) was also observed. Posttreatment, 15 patients (83.3%) reported a moderate or significant reduction in their bladder bother. Throughout the study, two adverse events were recorded with no causal relationship to the study treatment. DISCUSSION/CONCLUSIONS: Our study documented a significant reduction in all OAB symptoms and an improvement in all patient-reported outcomes in patients treated with peroneal eTNM® using the URIS® neuromodulation system.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nykturie $7 D053158
650    _2
$a hodnocení výsledků péče pacientem $7 D000071066
650    _2
$a výsledek terapie $7 D016896
650    12
$a hyperaktivní močový měchýř $x farmakoterapie $7 D053201
650    12
$a inkontinence moči $7 D014549
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rejchrt, Michal $u Department of Urology, 2nd Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czechia
700    1_
$a Skugarevska, Barbora $u Department of Urology, University Hospital, Ostrava, Czechia $u Department of Surgical Studies, Medical Faculty, Ostrava University, Ostrava, Czechia
700    1_
$a Grepl, Michal $u Department of Urology, University Hospital, Ostrava, Czechia $u Department of Surgical Studies, Medical Faculty, Ostrava University, Ostrava, Czechia
700    1_
$a Zvara, Peter $u Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark $u Department of Urology, Odense University Hospital, Odense, Denmark
773    0_
$w MED00004616 $t Urologia internationalis $x 1423-0399 $g Roč. 106, č. 7 (2022), s. 658-663
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35316811 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100511 $b ABA008
999    __
$a ok $b bmc $g 1854963 $s 1176790
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 106 $c 7 $d 658-663 $e 20220322 $i 1423-0399 $m Urologia internationalis $n Urol Int $x MED00004616
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options